Market Overview

Seattle Genetics Announces EC Conditional Marketing Authorization ADCETRIS

Seattle
Genetics (NASDAQ: SGEN) today announced that its collaborator, Millennium:
The Takeda Oncology Company, a wholly owned subsidiary of Takeda
Pharmaceutical Company Limited, announced that the European Commission
has granted conditional marketing authorization for ADCETRIS
(brentuximab vedotin). ADCETRIS was approved for two indications: (1)
the treatment of adult patients with relapsed or refractory
CD30-positive Hodgkin lymphoma (HL) following autologous stem cell
transplant (ASCT) or following at least two prior therapies when ASCT or
multi-agent chemotherapy is not a treatment option, and (2) for the
treatment of adult patients with relapsed or refractory systemic
anaplastic large cell lymphoma (sALCL). As a result, under the
collaboration Seattle Genetics will receive two milestone payments from

See full press release

Posted-In: News Guidance Contracts Management Global

 

Related Articles (SGEN)

Around the Web, We're Loving...

Get Benzinga's Newsletters